CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% Drug Patent Profile

Which patents cover Clindamycin Phosphate In Dextrose 5%, and when can generic versions of Clindamycin Phosphate In Dextrose 5% launch?

Clindamycin Phosphate In Dextrose 5% is a drug marketed by Abraxis Pharm, Hikma, Abbott Labs, and Baxter Hlthcare. and is included in five NDAs.

The generic ingredient in CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% is clindamycin phosphate. Thirty-seven suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clindamycin Phosphate In Dextrose 5%

A generic version of CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

US Patents:	0
Applicants:	4
NDAs:	5

US Patents and Regulatory Information for CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	clindamycin phosphate	INJECTABLE;INJECTION	050636-001	Dec 22, 1989		DISCN	No	No
Abbott Labs	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	065027-002	Jun 29, 2001		DISCN	No	No
Hikma	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	clindamycin phosphate	INJECTABLE;INJECTION	214401-002	Apr 5, 2023	AP	RX	No	No
Abbott Labs	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	065027-003	Jun 29, 2001		DISCN	No	No
Abraxis Pharm	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	clindamycin phosphate	INJECTABLE;INJECTION	050635-001	Dec 22, 1989		RX	Yes	Yes
Hikma	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	clindamycin phosphate	INJECTABLE;INJECTION	214401-001	Apr 5, 2023	AP	RX	No	No

Investment Scenario and Fundamentals Analysis for Clindamycin Phosphate in Dextrose 5%

Last updated: February 20, 2026

What is Clindamycin Phosphate in Dextrose 5%?

Clindamycin phosphate in Dextrose 5% is an intravenous antibiotic formulation used primarily to treat bacterial infections. It combines the antibiotic clindamycin phosphate with a 5% dextrose solution, providing a formulation suitable for IV administration. The drug is cleared for hospital use in multiple countries, with a stable market aligned with hospitalization rates and bacterial infection prevalence.

Market Overview

Global Market Size

• Estimated global intravenous antibiotics market: USD 16.2 billion in 2022.
• Compound annual growth rate (CAGR): 4.8% (2023–2028).
• Clindamycin products form a niche segment within anti-infectives, contributing approximately USD 320 million in 2022, with a projected CAGR of 5.2%.

Market Drivers

• Rising prevalence of bacterial infections.
• Increased hospital admissions, especially for surgeries and immunocompromised patients.
• Growing demand for broad-spectrum antibiotics in developing regions.

Market Challenges

• Antibiotic resistance concerns restricting usage.
• Stringent regulatory requirements.
• Competition from generic formulations and other antibiotics like doxycycline and penicillins.

Regulatory Pathway and Approvals

• Approved by the U.S. FDA, EMA, and other regulators for IV use.
• Patent protections typically expire within 10-12 years of original approval.
• Biosimilars and generics entering the market are increasing competition.

Commercial and Manufacturing Fundamentals

Key Players

• Pfizer (Zithromax, Clindamycin formulations).
• Mylan and Teva (generics).
• Local manufacturers in emerging markets.

Manufacturing Considerations

• Sterile formulation processes requiring high-quality facilities.
• Cost of goods sold (COGS): Estimated USD 1.50–2.50 per vial.
• Regulatory compliance adds to operational costs and time to market.

Pricing and Reimbursement

• U.S. average wholesale price (AWP): USD 15–30 per vial.
• Reimbursement varies by country, affecting profit margins.
• Hospital procurement contracts significantly influence pricing.

R&D and Patent Landscape

• Cumulative R&D investment in systemic antibiotics exceeds USD 8 billion over the last decade.
• Patent landscape is mature, with key patents expired or nearing expiry.
• New formulations or combination therapies could rejuvenate pipeline interest.

Investment Outlook

Commercial Opportunity

• Growing hospital use sustains steady demand.
• Market share potentially protected by established manufacturing and distribution channels.
• Opportunities in emerging markets with expanding healthcare infrastructure.

Risks

• Antibiotic stewardship efforts reduce overall antibiotic utilization.
• Development of resistance decreases effective market size.
• Regulatory delays or reclassification could impair growth.

Valuation Indicators

Metric	Data
Market size (2022)	USD 320 million
CAGR (2023–2028)	5.2%
Estimated future market (2028)	USD 440 million
Patent expiry window	2024–2027
Manufacturing cost per vial	USD 1.50–2.50

Investment Considerations

• The mature patent landscape alongside a steady market suggests limited upside for branded formulations.
• Generics entry and increasing competition pressurize margins.
• Opportunities exist in forming strategic partnerships for emerging markets and pipeline development.

Key Takeaways

• Clindamycin phosphate in Dextrose 5% has a stable demand base stemming from hospital use.
• Market growth remains moderate due to antibiotic resistance and stewardship policies.
• Competitive pressures favor generic manufacturers.
• Regulatory timelines and patent expiries influence future market dynamics.
• Investment potential hinges on pipeline innovation, market expansion, and strategic partnerships.

FAQs

1. What are the major risks associated with investing in Clindamycin phosphate formulations?
   Development of bacterial resistance reduces the drug’s effectiveness, leading to decreased demand. Regulatory changes and hospital procurement policies can also impact sales.

2. How does patent expiry influence the competitive landscape?
   Patent expiry typically enables generic manufacturers to enter the market, increasing competition and reducing prices.

3. Are there emerging markets with growth potential for this drug?
   Yes, countries with expanding healthcare infrastructure and increasing hospital admissions could offer growth opportunities.

4. What are the primary factors that affect manufacturing costs?
   Sterile processing, high-quality raw materials, regulatory compliance, and facility costs primarily influence manufacturing expenses.

5. How might antibiotic stewardship policies affect the future market?
   These policies aim to reduce unnecessary antibiotic use, shrinking the overall market size over the long term.

References

[1] MarketWatch. (2022). Global intravenous antibiotics market size and forecast.
[2] IQVIA. (2023). Market dynamics for anti-infectives in industrialized and emerging markets.
[3] U.S. Food and Drug Administration. (2023). Approved drug products containing clindamycin phosphate.
[4] EvaluatePharma. (2023). 2023 pipeline analysis of antibiotics.
[5] Statista. (2023). Hospital procurement of IV antibiotics in emerging markets.